"
Team:Queens/Project
From 2009.igem.org
(Difference between revisions)
| Line 64: | Line 64: | ||
Part One: Binding System | Part One: Binding System | ||
</p> | </p> | ||
| - | |||
| - | |||
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold"> | <p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold"> | ||
Part Two: Effector System | Part Two: Effector System | ||
</p> | </p> | ||
| - | |||
| - | |||
<p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold"> | <p style="font-size=150%;font-family:Corbel;color:#172C4E;font-weight:bold"> | ||
Part Three: Cleavage and Termination | Part Three: Cleavage and Termination | ||
Revision as of 04:48, 1 August 2009
Overview |
|
|
|
The QGEM project centres on the treatment of atherosclerosis by targeted drug delivery from E.coli. The project is broken down into three major components. The first, and the main, component is the cell membrane protein that allows E.coli to bind to the site of atherosclerotic plaque. The second component is the inducible effector system that produces factors to treat the plaque. The last component is the terminator system that detaches E.coli from the plaque and inhibits proliferation of E.coli in the blood stream. |
|
|
|
Part One: Binding System Part Two: Effector System Part Three: Cleavage and Termination |
